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Abstract
Background: Influenza A (flu) virus causes significant morbidity and mortality worldwide, and current vaccines require
annual updating to protect against the rapidly arising antigenic variations due to antigenic shift and drift. In fact, current
subunit or split flu vaccines rely exclusively on antibody responses for protection and do not induce cytotoxic T (Tc) cell
responses, which are broadly cross-reactive between virus strains. We have previously reported that c-ray inactivated flu
virus can induce cross-reactive Tc cell responses.
Methodology/Principal Finding: Here, we report that intranasal administration of purified c-ray inactivated human
influenza A virus preparations (c-Flu) effectively induces heterotypic and cross-protective immunity. A single intranasal
administration of c-A/PR8[H1N1] protects mice against lethal H5N1 and other heterotypic infections.
Conclusions/Significance: Intranasal c-Flu represents a unique approach for a cross-protective vaccine against both
seasonal as well as possible future pandemic influenza A virus infections.
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Introduction
The selection of virus strains for the formulation of current flu
vaccines is entirely based on ‘‘educated guesses’’ by comparing
recent virus isolates to known circulating human flu strains.
Prediction of flu strains that may cause infection in any flu season
(not pandemics) cannot accommodate the expected antigenic
variability arising due to virus mutations (genetic drift). For
example, the World Health Organization recommended the use of
A/Wisconsin/67/2005[H3N2]-like virus as part of the trivalent
inactivated vaccine for the Northern Hemisphere flu season 2007–
2008 [1]. Yet, according to the Centers for Disease Control and
Prevention, 65% of H3N2 influenza infections during the 2007–
2008 flu season in the US were caused by A/Brisbane/10/
2007[H3N2]-like viruses that evolved from A/Wisconsin/67/
2005[H3N2]-like virus and turned out to be antigenically distinct
virus that consequently rendered the vaccine ineffective [2]. This
illustrates the need for a new vaccine concept that maintains high
protective efficacy regardless of the antigenic variations that arise
frequently due to antigenic drift.
Chemically and UV inactivated influenza virus preparations
rely exclusively on antibody responses for protection and do not
induce cytotoxic T (Tc) cell responses [3]. The Tc cell response to
influenza is broadly cross-reactive between virus strains and is
important in the recovery from primary infections [4]. We have
previously reported that c-Flu preparations can induce cross-
reactive Tc cell responses [5]. Gamma-irradiation is the preferred
method of inactivation of highly infectious agents for biochemical
analysis, including Ebola, Marburg and Lassa viruses [6,7,8]. It
inactivates virus infectivity by generating strand-breaks in the
genetic material and has the further advantage, compared with
chemical agents, of high penetration into and through biological
materials [7]. In contrast to chemical treatment with formalin or
b-propiolactone (currently used in the production of inactivated
influenza virus vaccines), which induces cross-linking of proteins,
c-rays have little impact on the antigenic structure and biological
integrity of proteins [7]. The Manual on Radiation Sterilization of
Medical and Biological Material of the International Atomic
Energy Agency indicates that exposure to 0.65 kGy of c-rays
causes a total loss of influenza virus infectivity, but disrupting the
haemagglutinating activity requires an exposure to higher than
200 kGy [9]. The reduced impact of c-irradiation on the antigenic
structure of viral particles is therefore also expected to improve the
magnitude and/or quality of humoral immunity elicited in vaccine
recipients over that obtained by using present vaccine prepara-
tions. We have been investigating the ability of c-Flu preparations
to induce heterotypic and cross-protective immunity against avian
H5N1 influenza A virus. Our data clearly show that a single
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against lethal H5N1 and other heterotypic infections.
Materials and Methods
Mice
Nine- to ten-week-old female BALB/c mice were routinely used
in these studies. For H1 and H3 experiments, mice were obtained
and housed in Biosecurity Level 2 containment facilities at the
John Curtin School of Medical Research, the Australian National
University, ACT, Australia. For H5 studies, which were conducted
at the Australian Animal Health Laboratory (AAHL; Geelong,
Australia), mice were obtained from the Animal Resource Centre
(Perth, Australia), and all work using live virus was carried out
under Biosecurity Level 3 enhanced containment. All experimen-
tal procedures were approved by the institutional Animal Ethics
Committees.
Viruses and cells
P815 and Madin-Darby canine kidney (MDCK) cells were
maintained in F15 plus 5% foetal calf serum (FCS) and incubated
at 37uC in a humidified atmosphere with 5% CO2.
Stocks of influenza A viruses, (A/PR8 (A/Puerto Rico/8/34
[H1N1]), A/PC (A/Port Chambers/1/73 [H3N2]), A/JAP (A/
Japan/305/57 [H2N2]), and A/Vietnam/1203/2004[H5N1]),
were grown in embryonated hen eggs. Virus stocks were prepared
from allantoic fluid and stored in aliquots at 270uC. A/Vietnam/
1203/2004 was obtained from the WHO Collaborating Centre for
Reference and Research on Influenza (Melbourne, Australia).
Virus titration
Virus content for A/PR8[H1N1], A/PC[H3N2], and A/
JAP[H2N2] stocks were determined by standard plaque assay on
MDCK cells. Virus titres for these stocks were 8610
7 plaque
forming unit (PFU)/ml, 1610
7 PFU/ml, and 1610
7 PFU/ml,
respectively.
Titration of H5N1 infectivity was routinely undertaken by
infection of replicate Vero cell monolayers with 10-fold serial
dilutions of sample in Eagle’s minimum essential medium with
Earle’s salts (EMEM) containing 10% FCS and antibiotics. Plates
were incubated at 37uC for 5 days in 5% CO2, and the number of
replicate wells in each dilution series with cytopathic effect
determined. Titration of stock virus in 13-week-old female
BALB/c mice was performed by intranasal inoculation of groups
of 5 mice with 35 ml of 10-fold serially diluted virus in phosphate
buffered saline (PBS). Mice were monitored for development of
signs consistent with influenza infection for 10 days and were
euthanised if their clinical status met any of the following criteria:
loss of 20% of the pre-challenge body weight, development of any
neurological sign or an inability to eat or drink. Both 50% tissue
culture infectious dose (TCID50) and 50% mouse infectious dose
(MID50) titres were calculated using the method of Reed and
Muench [10]. For the stock H5N1 virus, the titre was 10
9.0
TCID50/ml or 10
7.0 MID50/ml.
c-Flu preparations
Stocks of A/PR8[H1N1] and A/PC[H3N2] were purified by
temperature-dependent adsorption to chicken red blood cells
(CRBC) [11]. Briefly, infectious allantoic fluids were incubated
with CRBC for 45 min at 4uC. Then, stocks were centrifuged at
12006g for 10 min and supernatants discarded. Pellets (CRBC
and attached viruses) were resuspended in normal saline and
incubated for 1 h at 37uC. Following incubation, samples were
centrifuged (12006g for 10 min), the supernatants collected and
virus titres estimated by plaque assays on MDCK cells. The
purified stocks were stored at 270uC, inactivated by exposure to
10 kGy of c-irradiation (Australian Nuclear Science and Tech-
nology Organization – ANSTO, Lucas Heights, Australia), and
tested for residual infectivity using embryonated hen eggs. These
stocks were sterile but retained full haemagglutinating activity after
irradiation.
51Cr-release cytotoxicity assay
A/PR8, A/PC or their corresponding c-Flu preparations
(2610
7 PFU equivalents per mouse) were administered intrave-
nously to 10-week-old BALB/c mice. Six days later, splenocytes
from infected, vaccinated, or mock-immunized animals were
harvested and tested for their killing activity on mock, A/PC-, A/
PR8- or A/JAP[H2N2]-infected target cells or labeled with the K
d
restricted nucleoprotein derived peptide TYQRTRALV (NPP)
using Cr
51 release assays, as previously described [12]. Red blood
cell depleted splenocytes (effectors) were mixed with labeled targets
at different ratios and incubated for 8 h at 37uC in a humidified
atmosphere containing 5% CO2. The level of radioactivity in
supernatants was measured and the specific lysis calculated using
the formula: (experimental cpm – spontaneous cpm)/(maximal
release cpm – spontaneous cpm)6100.
Vaccination and viral challenge
Mice were anaesthetised by intraperitoneal administration of
ketamine HCl (100 mg/kg) and xylazine HCl (10 mg/kg) prior to
vaccination or challenge. Mice were vaccinated by intranasal
administration of 32 ml (3.2610
6 PFU equivalents/mouse) of c-Flu
(c-A/PR8 or c-A/PC) divided equally between both nostrils.
Mock vaccinated mice received diluent alone (PBS). For H1 and
H3 studies, four weeks following vaccination, animals were
challenged intranasally with 6610
2 PFU/mouse of live virus (A/
PR8[H1N1] or A/PC[H3N2]), and mice were weighed prior to
infection and then daily for a period of 21 days.
For H5 studies, four weeks following vaccination, mice were
challenged with 35 ml (3 MID50) of H5N1 virus, divided equally
between nostrils. Two or three mice from each group were
euthanised on day 3 and 6 post-challenge, respectively, and right
lung and brain were collected for determination of viral genetic
load and infectivity, using separate sterile instruments for every
tissue to prevent cross contamination between samples. Tissues
were diced using separate sterile disposable scalpels and stored in
PBS, on ice, until transferred to 270uC for longer term storage.
The remaining 10 mice in each group were weighed daily (twice
daily once 15% body weight loss was detected), examined twice
daily for signs consistent with H5N1 infection, and euthanised
according to the experimental endpoints described earlier for
determination of MID50.
Homogenisation of tissues
Lung and brain homogenates were generated in 1 ml of PBS
using a Mini-BeadBeater-8 (Biospec Products, USA), and adjusted
to 10% (w/v) in PBS prior to extraction of viral RNA or titration
of infectivity.
Real-time RT PCR
Following the addition of 100 ml of lung or brain homogenate
into 600 ml of RLT buffer, RNA was extracted using an RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions.
The total RNA concentration of each sample was determined by
spectrophotometry and adjusted to 40 ng/ml with nuclease free
water. Standardised amounts (200 ng) of template were subse-
Intranasal Flu Vaccine
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scription Reagents kit (Applied Biosystems) in 20 ml reactions
following the recommendations of the manufacturer. For quan-
titation of viral cDNA, universal influenza virus type A-specific
primers and TaqMan probe, which amplified and detected a
product from within the viral matrix gene, were used [13].
Reactions were performed in triplicate and contained 12.5 mlo f
TaqMan 26Universal PCR Master Mix, 900 nM of each primer,
250 nM of probe, 2 ml of cDNA template and 6.8 ml of water.
Separate triplicate reactions to quantify 18S rRNA (TaqMan
Ribosomal Control Reagents, Applied Biosystems) were also
performed to exclude the presence of PCR inhibitors in all
samples tested. Reactions were performed in 96-well plates using
the 7500 Fast Real-Time PCR System (Applied Biosystems) and
the following cycling parameters: 50uC for 2 min; 95uC for
10 min; 45 cycles of 95uC for 15 sec and 60uC for 1 min. For
relative quantitation of viral genetic loads, a standard curve was
generated using, as template, 10-fold serial dilutions of extracted
stock virus RNA in 40 ng/ml of RNA prepared from uninfected
mouse lung. To facilitate interpretation of data, 1 unit (1 U) of
viral RNA was arbitrarily defined as the number of RNA
molecules which, when reverse transcribed and subjected to real-
time PCR, produced a CT value of 38.
Results
Gamma-Flu preparations induce cross-reactive cytotoxic
T cell responses
Virus stocks of two influenza A virus strains (A/PR8[H1N1]
and A/PC[H3N2]) were grown in embryonated hen eggs, purified
by temperature-dependent adsorption to chicken red blood cells
[11] and titrated by plaque assay on MDCK cells. The purified
stocks were exposed to 10 kGy of c-irradiation, and tested for
residual viral infectivity by using embryonated hen eggs and
plaque assay on MDCK cells. Virus stocks were sterile but
retained full haemagglutinating activity.
To test the ability of c-Flu to induce cross-reactive Tc cell
responses A/PR8, A/PC and their corresponding c-Flu prepara-
tions were used to infect or vaccinate mice. Six days later
splenocytes from infected, vaccinated, and mock-immunized
animals were tested for their killing activity on mock, A/PC-,
A/PR8-, A/JAP[H2N2]-infected or H-2K
d restricted nucleopro-
tein-derived peptide (NPP)-labeled P815 target cells using a
standard
51Cr release cytotoxicity assay [12]. All effector
splenocytes from flu-infected and c-Flu-vaccinated animals
expressed lytic activity against all influenza infected P815 targets
regardless of the virus strains used (Figure 1). In addition, all
splenocyte populations, except those from mock-infected mice,
killed NPP-labeled targets. Thus, c-Flu preparations induce cross-
reactive influenza-immune Tc cell responses in mice.
Routes of vaccination
Different routes of vaccination (intranasal (i.n.), intravenous
(i.v.), intraperitoneal (i.p.) and subcutaneous (s.c.)) were used to
immunize BALB/c mice (10 mice/group) with 3.2610
6 PFU
equivalents of c-Flu (c-A/PC[H3N2]). Three weeks post vaccina-
tion mice were challenged i.n. with a lethal dose of live A/
PR8[H1N1] (6610
2 PFU) and monitored for mortality and
clinical signs using 30% body weight loss as the end point
(Figure 2). All i.n. vaccinated animals fully recovered with little, if
any, weight loss after challenge with the heterotypic virus
(Figure 2C). In contrast, the majority of mock vaccinated
Figure 1. Cross-reactive cytotoxic T cell responses induced by c-Flu. 10-week-old BALB/c mice were either infected or vaccinated with live A/
PR8, c-A/PR8, live A/PC, or c-A/PC. Six days later, splenocytes from these mice were tested for their killing activity against mock, A/PC-, A/PR8-, A/JAP-
infected, and NPP-labelled P815 targets. Data represent % specific lysis after 6 h assay time at an effector to target cell ratio of 120:1.
doi:10.1371/journal.pone.0005336.g001
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(data not shown) mice lost weight progressively to reach 30% body
weight loss by days 7 or 8 post-challenge. The survival data
(Figure 2D) show that despite the use of high challenge doses of A/
PR8[H1N1], i.n. vaccinated mice survived the heterotypic
challenge at significant levels (P,0.05 using Fisher’s Exact test).
In addition, mice vaccinated with c-A/PC or c-A/PR8 survived
both heterotypic and homotypic challenges with 506 the lethal
dose of A/PR8 (data not shown). Thus, c-Flu represents a new
vaccine concept that induces highly efficient heterotypic protection
against influenza A strains.
Intranasal vaccination with c-A/PR8[H1N1] protects
against lethal H5N1 infection
To determine the extent to which the heterotypic immunity
induced by c-Flu preparations of human influenza A viruses
extends to avian isolates, we tested the protective efficacy of c-A/
PR8[H1N1] using a mouse model of H5N1 highly pathogenic
avian influenza. BALB/c mice (15 mice/group) were vaccinated
i.n. with a single dose of c-A/PR8[H1N1] (3.2610
6 PFU
equivalents/mouse). Four weeks later, under Biosecurity Level 3
enhanced containment, mice were challenged i.n. with 36 the
50% mouse infectious dose (3 MID50) of A/Vietnam/1203/
2004[H5N1]. Two or three mice from each group were
euthanised on day 3 and 6 post-challenge, respectively, for
determination of viral genetic load and infectivity in lung and
brain, while the remaining 10 mice in each group were monitored
for development of clinical signs and loss of body weight (Figure 3).
All ten mice in the mock vaccinated group developed clinical signs
consistent with H5N1 infection and were euthanised between days
7 and 14 post-challenge in accordance with the experimental end
points that were approved by the institutional animal ethics
committees (weight loss of 20%, development of any neurological
sign, or inability to eat or drink) (Figure 3A). Mock vaccinated
mice developed greasy, ruffled fur from day 4 post-challenge,
which progressively worsened until euthanised. Two mice
developed neurological signs categorized by an abnormal hind
limb gait and hind limb weakness, at which time each was
euthanised (day 9 or 14 post-challenge), while all other mice were
euthanised at ,17–22% body weight loss with varying degrees of
depression, inactivity and dehydration. In contrast, all vaccinated
mice (c-A/PR8[H1N1]) remained bright and active throughout
the study and were euthanised at the conclusion of the trial on day
21 post-challenge (Figure 3B). Although one mouse had lost
,11% body weight by day 4 post-challenge, it was otherwise
bright and active, and had regained its pre-challenge weight by the
end of the trial. Furthermore, despite most mice having lost up to
,7–8% body weight from day 6 through to 12 post-challenge, all
gained weight thereafter such that all but three had reached or
exceeded their pre-challenge weight by day 21 post-challenge.
Therefore, our data demonstrate that a single dose of c-Flu
administered i.n. induces cross-protective immunity in mice
against a lethal challenge with H5N1 virus. Quantitation of viral
infectivity and viral genetic loads in lung and brain confirmed the
protective effect of c-A/PR8[H1N1] against avian influenza and
demonstrated clearance of H5N1 virus from lung tissues by day 6
Figure 2. Intranasal vaccination with c2Flu provides superior protection to heterotypic virus challenge. Groups of 10 BALB/c mice
were either mock treated (A) or vaccinated with c2A/PC (3.2610
6 PFU equivalents) intravenously (B) or intranasally (C). Mice were challenged
intranasally after 3 weeks with a lethal dose (6610
2 PFU) of A/PR8 and weight recorded daily for 21 days. Survival (D) of mice mock treated, or
vaccinated i.n., i.v., i.p., or s.c. and challenged as for (A–C) and monitored for 21 days.
doi:10.1371/journal.pone.0005336.g002
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RNA in the lung of 1 vaccinated mouse on day 3 post-challenge
but not on day 6 indicates that the observed cross-protective
immunity is most likely mediated by memory Tc cells, which
express accelerated activation kinetics over that of naı ¨ve Tc cells
[14]. We also have preliminary data showing that passive transfer
of CD8
+ T cells, but not serum, from mice vaccinated 6 days
previously with c-Flu can confer protection against lethal
heterotypic infection (Furuya et al, in preparation).
Discussion
Human influenza A viruses bind to a2,6-linked sialic acid
receptors expressed on epithelial cells of the upper respiratory tract
of humans, whereas avian influenza H5N1 viruses bind to a2,3-
linked receptors expressed predominantly in the lower respiratory
tract [15,16] In general, binding of virus to a2,6-linked receptors is
associated with low virulence but high transmissibility. In contrast,
virus binding to a2,3-linked receptors is associated with low
transmissibility but high virulence and often lethal influenza virus
infections [16]. Therefore, an avian influenza pandemic might be
expected to be associated with a mutation in the haemagglutinin
molecule that would allow H5N1 virus to bind to a2,6-linked
receptors. Subunit vaccines based on currently identified H5
molecules cannot account for the antigenic variants that would
result following such mutations and, consequently, neutralizing
antibody-mediated protection induced by these vaccines would
likely be limited. Tc cell responses to influenza infection, however,
are mainly directed against internal viral proteins, which are
highly conserved among all influenza A virus strains [4].
Mutations of internal genes are not susceptible to antibody-
mediated selection and viral escape from Tc cell responses is
curtailed by MHC class I polymorphism. Therefore, vaccines
inducing Tc cell responses against the highly conserved internal
proteins, such as the nucleoprotein, are expected to provide cross-
protection against different influenza A virus strains [17,18]. Our
data indicate that the cross-reactive Tc cell responses induced by
c-Flu are predominantly directed against the internal proteins,
indicated by lysis of NPP-labeled targets (Figure 1D).
The Tc cell response is broadly cross-reactive between influenza
A strains and is important for recovery from primary infections in
combination with antibodies [19,20] Furthermore, cross-recogni-
tion of avian H5N1 influenza virus by human Tc-lymphocyte
populations induced by human influenza A virus has recently been
reported [21]. We have previously discussed the potential
applicability of c-Flu as vaccine candidates to induce cross-
protective immunity and envisaged two, not exclusive, mecha-
nisms to induce efficient Tc cell responses: efficient cellular uptake
of c-Flu and abortive translation of fragmented genomes [22].
While the abortive translation represents a very remote possibility
due to the negative strandedness of the influenza virus genome, an
efficient cellular uptake of c-irradiated virus particles is the most
likely mechanism to the induction of Tc cell responses.
Nonetheless, the ability to induce Tc cell responses should be
considered a highly desirable property of an inactivated influenza
virus vaccine candidate. This, however, does not exclude the
importance of antibodies, including the possibility of an enhanced
cross-protective antibody response. The underlying mechanisms
for the cross-protective immunity are currently under investiga-
tion, and our preliminary data strongly point to a Tc cell mediated
mechanism. This is based on the following observations. One,
passive transfer of T cells, but not B cells or serum, from
immunised mice protects naı ¨ve mice from heterotypic influenza
infections. Two, MHC class I deficient mice (beta-2 microglobulin
knock out) are not protected against heterotypic challenge and
Figure 3. Intranasal vaccination with c2Flu (c2A/PR8[H1N1])
protects against H5N1 challenge. Groups of 10 BALB/c mice were
either mock treated (A) or vaccinated with c2A/PR8 (B). Mice were
challenged 4 weeks later with 3 MID50 of A/Vietnam/1203/2004[H5N1]
intranasally and weight recorded daily for 21 days.
doi:10.1371/journal.pone.0005336.g003
Table 1. H5N1 infectivity and viral genetic loads in lung and
brain.
Day* Treatment Mouse Infectivity Genetic load
Lung Brain Lung Brain
Mock 1 6.5 #3.2 3.460.03 -{
3 2 5.8 - 2.060.02 -
Vaccinated 1 - - - -
2 7.4 - 3.660.02 -
Mock 1 6.4 - 4.260.003 -
6 2 6.4 - 4.260.01 -
3 7.4 5.0 4.460.03 3.060.03
Vaccinated 1 - - - -
2- -- -
3- -- -
NOTE. Viral infectivity and relative viral genetic loads are expressed as log10
TCID50/g and log10 U per 20 ng of extracted RNA (geometric mean6s.d. of
triplicate reactions), respectively, where 1 unit (1 U) of viral RNA is arbitrarily
defined as the number of RNA molecules which, when reverse transcribed and
subjected to real-time PCR, produced a CT value of 38.
*Day post-challenge.
{Undetectable (,10
3.2 TCID50/g (infectivity) or ,1 U per 20 ng of extracted
RNA (genetic load)).
doi:10.1371/journal.pone.0005336.t001
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immunized mice are challenged with lethal doses of live
heterotypic viruses (Furuya et al, manuscript in preparation). In
addition it is of interest and supports our contention of a Tc cell
mediated mechanism that gamma-flu like live virus induces Tc cell
responses while other virus inactivation procedures (formalin or
UV inactivation) as well as commercially available flu vaccines are
unable to do so (Furuya et al submitted).
Given the importance of obtaining improved heterotypic
immunity and protection, our novel vaccine concept may
overcome the poor efficacy of present influenza vaccines against
antigenic variants arising following host range mutations in
virulent avian or porcine strains. Therefore, c-Flu represents a
novel vaccine concept, with the potential to protect not only
against seasonal flu infections but also possible avian flu
pandemics. Unlike experimentally attenuated (cold adapted)
viruses, c-Flu is unable to revert to live virulent virus. We do
not yet fully understand why c-Flu is eliciting immunity similar to
that obtained with live virus. However, the observation that c-Flu,
unlike other c-ray inactivated viruses [23], induces a vigorous
Type I interferon response with an accompanying partial systemic
lymphocyte activation (Furuya et al, unpublished data) may be at
least partially responsible for its superior immunogenicity.
Furthermore, intranasal vaccination would make administration
of such a vaccine preparation highly advantageous in developing
countries and high priority should be given to evaluating its
efficacy in humans.
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